Ivosidenib maintenance for IDH1-mutated bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a targeted pill called ivosidenib for people with a specific type of bile duct cancer (IDH1-mutated) who have completed surgery and chemotherapy. The goal is to see if taking ivosidenib as a maintenance therapy helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You had surgery to remove your bile duct cancer completely, with no signs of cancer left behind
- Your tumor has a specific change called an IDH1 mutation
- You have finished chemotherapy after surgery to lower the risk of cancer returning
- You are in good overall health, able to do your daily activities without help
- You are willing to provide blood and tumor samples for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well the drug ivosidenib works for people with a certain type of bile duct cancer (cholangiocarcinoma) that has a specific change in the IDH1 gene. It is for people whose cancer has spread or cannot be removed by surgery and who have already tried at least one other cancer treatment.
This trial tests whether taking ivosidenib after a stem cell transplant can help prevent leukemia from coming back in people with a specific gene change called IDH1. It may be an option if you have AML or MDS with that mutation and are recovering from transplant.
This trial tests whether taking ivosidenib as a maintenance drug (to keep the cancer in remission) works better than standard care for patients with IDH1-mutated AML or high-risk MDS who cannot undergo a bone marrow transplant. Ivosidenib is a targeted drug that blocks a specific mutation found in your cancer.
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
This trial tests a new combination of three drugs (ivosidenib, durvalumab, and gemcitabine/cisplatin) as a first treatment for people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests an oral drug (ivosidenib) for people with IDH1-mutated cancers who also have liver or kidney problems. It aims to find the right dose and see how safe and effective it is for these patients.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.